Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Zollinger-Ellison Syndrome

Treatments: Drug: Esomeprazole magnesium (Nexium)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00079833

D9612C00025

Details and patient eligibility

About

This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females at least 18 years of age.
• Diagnosis of Zollinger-Ellison Syndrome or idiopathic hypersecretion

Exclusion criteria

• Pregnant or lactating females
• History of drug addiction or alcohol abuse within 12 months prior to Screening.
• History of intolerance to any proton pump inhibitors or any ingredient in their formulation.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)